Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Aug;33(8):1195-1197.
doi: 10.1038/s41433-019-0407-1. Epub 2019 Apr 2.

Cochrane Corner: Ocriplasmin-why isn't it being used more?

Michael Grinton  1 , David H Steel  2
Affiliations
Editorial

Cochrane Corner: Ocriplasmin-why isn't it being used more?

Michael Grinton et al. Eye (Lond). 2019 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

DHS is a consultant to Alcon and Oxurion. The remaining author declares that he has no conflict of interest.

References

    1. National Institute for Health and Care Excellence (NICE). Ocriplasmin for treating vitreomacular traction: Technology appraisal guidance. Available from: nice.org.uk/guidance/ta297. 2013.
    1. Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola S, et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med. 2012;367:606–15. doi: 10.1056/NEJMoa1110823. - DOI - PubMed
    1. Neffendorf JE, Kirthi V, Pringle E, Jackson TL. Ocriplasmin for symptomatic vitreomacular adhesion. Cochrane Database Syst Rev2017, Issue 10. Art. No.: CD011874. 10.1002/14651858.CD011874.pub2. - PMC - PubMed
    1. Chatziralli I, Theodossiadis G, Xanthopoulou P, Miligkos M, Sivaprasad S, Theodossiadis P. Ocriplasmin use for vitreomacular traction and macular hole: a meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications. Graefes Arch Clin Exp Ophthalmol. 2016;254:1247–56. doi: 10.1007/s00417-016-3363-5. - DOI - PubMed
    1. Dugel PU, Tolentino M, Feiner L, Kozma P, Leroy A. Results of the 2-year ocriplasmin for treatment for symptomatic vitreomacular adhesion including macular hole (OASIS) randomized trial. Ophthalmology. 2016;123:2232–47. doi: 10.1016/j.ophtha.2016.06.043. - DOI - PubMed

Publication types

MeSH terms